# US 2013/0251691 A1 · Embryonic Stem Cell-Derived Cardiomyocytes and a Cellular Therapeutic Agent Comprising the Same as an Active Ingredient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0251691 A1
- Document ID: US20130251691A1
- Status: Published application
- Kind: A1
- Application number: 13/907,967
- Filed: 2013-06-02
- Published: 2013-09-26
- Earliest claimed: 2010-10-06
- Assignees: Chabio & Diostech Co., Ltd.
- Applicants: Chabio & Diostech Co., Ltd.
- Inventors: Hyung Min Chung; Sung Hwan Moon
- Web page: https://patentgrep.com/patent/US20130251691A1

## CPC

- C12N 5/0657: {Cardiomyocytes; Heart cells}
- A61K 35/34: Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44)
- C12N 2506/02: from embryonic cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a method for producing embryonic stem cell-derived cardiomyocytes, cardiomyocytes produced by the method, a method for producing cardiomyocyte bodies from the cardiomyocytes, cardiomyocyte bodies produced by the method, a cellular therapeutic agent comprising the cardiomyocyte bodies as an active ingredient for the treatment of cardiac diseases, a method for treating cardiac diseases using the cellular therapeutic agent, and use of cardiomyocytes or cardiomyocyte bodies for the preparation of the cellular therapeutic agent. The method for producing cardiomyocytes of the present invention can be used to easily purify differentiated cardiomyocytes from embryonic stem cells. Further, the purified cardiomyocytes can be used to produce cardiomyocyte bodies, which can be used as a cellular therapeutic agent for treating cardiac diseases. Therefore, the cardiomyocyte bodies can be widely applied to the development of prophylactic or therapeutic agents for cardiac diseases.

## Claims

### Claim 1

A method for producing cardiomyocytes from embryonic stem cells, comprising:
(a) culturing embryonic stem cells to obtain a culture; and
(b) culturing the culture in a serum-free medium to purify cardiomyocytes.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the embryonic stem cells are human embryonic stem cells or mouse embryonic stem cells.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the serum-free medium comprises insulin, transferrin, progesterone, putrascine, and selenite.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the serum-free medium comprises N2 supplement.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the serum-free medium is a DMEM medium comprising N2 supplement.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the culture comprises embryoid bodies.

### Claim 7 (depends on 1)

The method according to claim 1, further comprising isolating the culture at a cellular level after step (a).

### Claim 8 (depends on 1)

Cardiomyocytes produced by the method of claim 1, having the following characteristics of:
(i) expressing a marker selected from the group consisting of α-actinin, troponin I (cTn I), ANP, GATA4, Nkx2.5, MEF-2c, MYH6, MYH7, Con43, myosin heavy chain (α-MHC or sMHC), myosin light chain (MLC-2α or MLC-2v), cardiac actin, cTnT and cTnl;
(ii) having a cyst-like shape, a mixed shape, a floating or muscle-like shape; and
(iii) showing pulsatile beating.

### Claim 9

A method for producing cardiomyocyte bodies, comprising:
(a) culturing embryonic stem cells to obtain a culture;
(b) culturing the culture in a serum-free medium to purify cardiomyoblasts; and
(c) culturing the purified cardiomyoblasts in a serum-free medium.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the serum-free medium comprises insulin, transferrin, progesterone, putrascine, and selenite.

### Claim 11 (depends on 9)

The method according to claim 9, wherein the serum-free medium comprises N2 supplement.

### Claim 12 (depends on 9)

The method according to claim 9, wherein the serum-free medium is a DMEM medium comprising N2 supplement.

### Claim 13 (depends on 9)

The method according to claim 9, wherein the cardiomyocyte bodies show synchronized beating.

### Claim 14 (depends on 9)

The method according to claim 9, wherein the cardiomyocyte bodies have a diameter of 200 to 500 um.

### Claim 15 (depends on 9)

Cardiomyocyte bodies produced by the method of claim 9.

### Claim 16 (depends on 15)

A cellular therapeutic agent for treating cardiac diseases, comprising cardiomyocyte bodies of claim 15 as an active ingredient.

### Claim 17 (depends on 16)

The cellular therapeutic agent according to claim 16, wherein the cardiomyocyte bodies show synchronized beating.

### Claim 18 (depends on 16)

A method for treating cardiac diseases, comprising administering a therapeutically effective amount of the cellular therapeutic agent of claim 16 to a subject.
